Infektionen der Atemwege mit Pseudomonas aeruginosa bei der Cystischen Fibrose
- 1 June 1985
- journal article
- review article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 63 (11) , 490-498
- https://doi.org/10.1007/bf01747978
Abstract
The main cause of death in cystic fibrosis (CF) patients is progressive pulmonary insufficiency frequently associated with chronic infections of the respiratory tract by Pseudomonas aeruginosa. Bacteria of this species synthesize numerous extracellular products contributing to its pathogenicity. An alginate-like exopolysaccharide is characteristic for mucoid mutants predominating among P. aeruginosa isolates from CF patients. It interferes with immune defense mechanisms of the host and probably protects the bacteria against certain antibiotics. Furthermore, it is involved in the formation of bacterial microcolonies that resist mucociliary clearance, opsonisation, and phagocytosis. Exotoxin A and elastase are regarded as the most important among various extracellular enzymes involved in pulmonary injury in CF patients. Exotoxin A inhibits eukaryotic protein synthesis leading to necrosis; elastase, together with other Pseudomonas-proteases, induces hemorrhagic lesions and necrosis and seems to inactivate immunoglobulins and complement factors. Phospholipase C and glycolipid represent two hemolysins of P. aeruginosa that may contribute to cytopathogenic effects in infected lungs. No primary defect in the immunological defense mechanisms of CF patients has been described so far. Antibodies against various P. aeruginosa antigens including those mentioned above have been demonstrated, but a complete elimination of the bacteria from infected lungs has not been observed. Therapy of pulmonary P. aeruginosa infections in CF patients usually includes combinations of antibiotics of theβ-lactam and aminoglycoside type. Difficulties arise from an unusually high intrinsic resistance of P. aeruginosa as well as from poor penetration of many antibiotics into the sputum of CF patients. Therefore, future efforts to manage the Pseudomonas problem in CF will probably concentrate on prophylactic therapy, e.g. childhood vaccination of CF patients in order to prevent bacterial colonization of the respiratory tract.This publication has 159 references indexed in Scilit:
- Quantitation and Identification of Antibodies to Outer-Membrane Proteins of Pseudomonas aeruginosa in Sera of Patients with Cystic FibrosisThe Journal of Infectious Diseases, 1984
- Pseudomonas cepacia infection in cystic fibrosis: An emerging problemThe Journal of Pediatrics, 1984
- A novel biological function of alginate inPseudomonas aeruginosaand its mucoid mutants: stimulation of exolipaseFEMS Microbiology Letters, 1984
- Determinants of the Biologic Activity of Surface Slime In Experimental Pseudomonas aeruginosa InfectionsClinical Infectious Diseases, 1983
- The serum sensitivity, colonial morphology, serogroup specificity, and outer membrane protein of Pseudomonas aeruginosa strains isolated from several clinical sitesDiagnostic Microbiology and Infectious Disease, 1983
- PROGNOSIS FOR SURVIVAL WITH CYSTIC FIBROSIS: THE EFFECTS OF EARLY DIAGNOSIS AND CYSTIC FIBROSIS CENTER CAREActa Paediatrica, 1982
- Isolation of Alginate-producing Mutants of Pseudomonas fluorescens, Pseudomonas putida and Pseudomonas mendocinaMicrobiology, 1981
- Antimicrobial susceptibility of mucoid Pseudomonas aeruginosa and their spontaneously occurring non-mucoid derivativesJournal of Antimicrobial Chemotherapy, 1980
- The Instability of Mucoid Pseudomonas aeruginosa: Fluctuation Test and Improved Stability of the Mucoid Form in Shaken CultureJournal of General Microbiology, 1979
- An atypical Pseudomonas aeruginosa associated with cystic fibrosis of the pancreasThe Journal of Pediatrics, 1966